T2DM
Clinical trials for T2DM explained in plain language.
Never miss a new study
Get alerted when new T2DM trials appear
Sign up with your email to follow new studies for T2DM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Diabetes drug semaglutide under scrutiny for bone risks
Disease control Not yet recruitingThis study looks at whether semaglutide, a common diabetes drug, affects bone density and fracture risk in people with type 2 diabetes. About 150 adults aged 50-75 will take either semaglutide plus metformin or metformin alone for 12 months. Researchers will measure bone density …
Matched conditions: T2DM
Phase: PHASE4 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
New drug aims to protect kidneys in diabetes patients
Disease control Not yet recruitingThis study tests whether the investigational drug HTD1801 can slow the worsening of kidney disease in adults who have both type 2 diabetes and chronic kidney disease. About 75 participants will receive either HTD1801 or a placebo twice daily for 12 weeks. The main goal is to see …
Matched conditions: T2DM
Phase: PHASE2 • Sponsor: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New diabetes drug HM15275 enters Mid-Stage trial
Disease control Not yet recruitingThis study tests a new medicine called HM15275 for people with type 2 diabetes. About 180 adults who manage their diabetes with diet and exercise or metformin will receive either the drug or a placebo for 36 weeks. The main goal is to see if the drug improves blood sugar control,…
Matched conditions: T2DM
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New drug combo aims to tackle diabetes and fatty liver together
Disease control Not yet recruitingThis study is testing whether adding a third diabetes drug (alogliptin) to a standard two-drug combination (pioglitazone and metformin) works better for people who have both type 2 diabetes and fatty liver disease. Researchers will enroll 80 participants to see if the three-drug …
Matched conditions: T2DM
Phase: PHASE4 • Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
Sleep and menopause may harm diabetic women's hearts, study finds
Knowledge-focused Not yet recruitingThis study looks at how menopause and poor sleep affect the heart in women with type 2 diabetes. Researchers will track 381 women aged 48-58 to measure changes in heart function using ultrasound. The goal is to understand these links, not to test a treatment.
Matched conditions: T2DM
Sponsor: Ottawa Heart Institute Research Corporation • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC